BARCELONA—There was no improvement in biochemical progression free survival among patients who had their high-risk localized prostate cancers treated with elective pelvic nodal irradiation compared with those who had prostate radiation only. That was the finding of a sub-analysis of 358 patients from the GETUG 12 phase-III trial treated with primary radiotherapy. Study author Pierre Blanchard MD PhD, from Gustave Roussy in Villejuif, France, gave Oncology Times reporter Sarah Maxwell the details after he presented the results to the 3rd ESTRO Forum (April 24-28, 2015).
You may also like...
IGNITE Study: More Asians than Russians with Mutant EGFR Lung Adenocarcinoma; Adjuvant Erlotinib for Stage IIIA-N2 Disease 27 Apr, 2015 Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013 Complexity And Lack Of Independence — Hazards For Humanitarian Organisations Intervening In Disasters 21 Jun, 2011 BREAST CANCER: Intraoperative radiotherapy at the time of lumpectomy is as effective as whole breast irradiation and associated with fewer non-cancer deaths 19 Nov, 2013
- Previous story Combined Intracavitary/Interstitial Brachytherapy: New benchmark for Cervical Cancer
- Next story ARCON Improved Quality of Life in Advanced Laryngeal Cancer: Phase-III ARCON Trial
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014